Martin Fitchet

Martin Fitchet, M.D., is CEO of Medicines for Malaria Venture (MMV), a leading product development partnership in the field of antimalarial drug research & development. In this position he is working with the dedicated MMV team and their partners to accelerate innovation and access for malaria medicines, with an ultimate goal to eradicate the disease.

 Before becoming the CEO of MMV, Martin Fitchet was Head of Global Public Health (GPH) at Johnson & Johnson, where he led a dedicated end-to-end organization focusing on R&D, access and last-mile implementation in tuberculosis, HIV, Ebola, and neglected tropical diseases.

 Originally joining Johnson & Johnson in 2000, Dr Fitchet assumed positions of increasing responsibility in Research & Development (R&D) including Global Therapeutic Area (TA) Head for Cardiovascular & Metabolism, Chief Operating Officer and Global TA Head for Pulmonary Hypertension. Dr Fitchet also led Global R&D for Johnson & Johnson Medical devices, across the three Medical Devices franchises: DePuy Synthes Orthopedics, Ethicon General Surgery, and Cardiovascular & Specialty Solutions.

 Dr Fitchet has also held scientific leadership positions in Medical Affairs and Research & Development in metabolism and diabetes for Sanofi Aventis and Novartis.

 Having earned his degree at the University of Nottingham Medical School in Nottingham, UK, he became a Fellow of the Royal College of Surgeons of England in 1995, and later a member of The Faculty of Pharmaceutical Medicine in London, UK.